Compound 1 is efficient at the molecular (IC50 = 0.3 nM for pim‐1 and pim‐2) and cellular level (IC50 = 23 nM in KMS‐12 BM), and is also an efficient therapeutic in the myeloma model of mice from KMS‐12 BM with 78% TGI at 50 mg/kg QD.81 Here, PIM1 is linked to plasma cell myeloma.